Research & Development
Airway Therapeutics collaborates with Celonic Group to produce AT-100 (rhSP-D) COVID-19 candidate
21 May 2020 -

United States-based Airway Therapeutics Inc has collaborated with Switzerland-based Celonic Group to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19 it was reported on Wednesday.

According to the contract, Celonic will be responsible for process optimisation and GMP manufacturing of AT-100 for clinical study. Production of AT-100 is likely to commence in June 2020.

The product is an engineered version of an endogenous protein that has indicated in preclinical studies to decrease inflammation and infection in a range of bacterial and viral respiratory diseases by modulating the body's immune response. Airway has earlier filed a pre-IND submission with the United States Food and Drug Administration (FDA) for AT-100 as a preventive treatment of the serious respiratory disease bronchopulmonary dysplasia in very preterm infants, with an IND filing likely in the third quarter and plans to enter the clinic in late 2020.

'AT-100 has shown great potential in addressing the inflammation and injury caused by serious respiratory diseases driven by infection but has never been produced for larger-scale clinical trial indications,' said Marc Salzberg, MD, Airway president and CEO. 'Airway has dedicated significant time and resources to develop a manufacturing process for AT-100 – leading the path to clinical development. Given the urgency of the current pandemic, I am thrilled to establish this collaboration with Celonic, a leader in biologic manufacturing, to increase the scale of our production capabilities with the potential to meet the needs of patients.'